Who Paid My Doc
Benjamin Medoff
Critical Care Medicine Boston, MA Medical Doctor
NPI 1720062300 CMS profile 640087
55 Fruit St, Pulmonary And Critical Care, Bul 148, Boston, MA 02114
General payments
$97,768
Research payments
$1,089
Ownership & investment interest
$0
Research they led as principal investigator
$1,169,684
Through program year 2025, Benjamin Medoff of Boston, MA is reported in the CMS Open Payments database as having received $97,768 across 51 general payments and $1,089 in research payments paid to them. Separately, studies naming them as principal investigator received $1,169,684 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $469 | 4 | |
| 2024 | General | $63 | 2 | |
| 2024 | Research | $1,089 | 9 | |
| 2023 | General | $61,165 | 27 | |
| 2022 | General | $10,013 | 1 | |
| 2021 | General | $5,910 | 3 | |
| 2020 | General | $12,871 | 6 | |
| 2019 | General | $7,277 | 8 |
Beside peers
- Benjamin Medoff
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Benjamin Medoff were reported at $469. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Benjamin Medoff | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,277 | $149 | $51–$535 | $163 |
| 2020 | $12,871 | $110 | $30–$325 | $114 |
| 2021 | $5,910 | $125 | $34–$403 | $132 |
| 2022 | $10,013 | $157 | $49–$582 | $149 |
| 2023 | $61,165 | $162 | $56–$621 | $160 |
| 2024 | $63 | $168 | $53–$634 | $164 |
| 2025 | $469 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
203
Drug cost
$123,290
Branded share of claims
78.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 18 | $65,843 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 25 | $25,723 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 27 | $11,450 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 13 | $9,869 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 31 | $5,200 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 14 | $3,109 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 31 | $1,352 | |
| Omeprazole | Generic | 20 | $388 | |
| Azithromycin | Generic | 12 | $319 | |
| Prednisone | Generic | 12 | $36 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$31,962
Medicare patients
168
Services billed
284
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| COPD | 63% | |
| Ischemic heart disease | 51% | |
| Arthritis | 49% | |
| Heart failure | 40% | |
| Chronic kidney disease | 40% | |
| Depression | 35% | |
| Diabetes | 32% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| DUPIXENT |
|
$21 | 18 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
60 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Massachusetts
Richard Channick
Critical Care Medicine · Boston, MA
Ioana Preston
Critical Care Medicine · Burlington, MA
Mark Tidswell
Critical Care Medicine · Springfield, MA
William McGee
Critical Care Medicine · Springfield, MA
Diana Espinoza Barrera
Critical Care Medicine · Boston, MA
Raghu Seethala
Critical Care Medicine · Weymouth, MA
Related records
Critical Care Medicine in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.